PT  - JOURNAL ARTICLE
AU  - Zaid Zoumot
AU  - Claire Davey
AU  - Simon Jordan
AU  - William H McNulty
AU  - Denis H Carr
AU  - Matthew D Hind
AU  - Michael I Polkey
AU  - Pallav L Shah
AU  - Nicholas S Hopkinson
TI  - Endobronchial valves for patients with heterogeneous emphysema and without interlobar collateral ventilation: open label treatment following the BeLieVeR-HIFi study
AID  - 10.1136/thoraxjnl-2016-208865
DP  - 2017 Mar 01
TA  - Thorax
PG  - 277--279
VI  - 72
IP  - 3
4099  - http://thorax.bmj.com/content/72/3/277.short
4100  - http://thorax.bmj.com/content/72/3/277.full
SO  - Thorax2017 Mar 01; 72
AB  - Outcomes in early trials of bronchoscopic lung volume reduction using endobronchial valves for the treatment of patients with advanced emphysema were inconsistent. However improvements in patient selection with focus on excluding those with interlobar collateral ventilation and homogeneous emphysema resulted in significant benefits in the BeLieVeR-HIFi study compared with sham treated controls. In this manuscript we present data from the control patients in the BeLieVeR-HIFi study who went on to have open label endobronchial valve treatment after completion of the clinical trial (n=12), combined with data from those in the treatment arm who did not have collateral ventilation (n=19). Three months after treatment FEV1 increased by 27.3 (36.4)%, residual volume reduced by 0.49 (0.76) L, the 6 min walk distance increased by 32.6 (68.7) m and the St George Respiratory Questionnaire for COPD score improved by 8.2 (20.2) points. These data extend the evidence for endobronchial valve placement in appropriately selected patients with COPD.Trial registration number: ISRCTN04761234; Results.